hVIVO

Historical price data

hVIVO operates as a full-service early-phase CRO, uniquely positioned as the global leader in human challenge trials for infectious and respiratory diseases. The company leverages over 14 validated challenge models, a database of over 400,000 volunteers, and world-class quarantine and laboratory facilities to accelerate drug development for its pharmaceutical and biotech clients. Its integrated service offering spans clinical trial design, execution, regulatory support, and specialized laboratory services, providing an end-to-end solution for early clinical development.

World-leading human challenge trial platform featuring over 14 validated models for controlled human infection, supported by specialized quarantine facilities and virology/immunology laboratories to accelerate proof-of-concept studies.

10 drugs in pipeline

hVIVO competes with large, full-service CROs (e.g., IQVIA, ICON) and niche early-phase CROs, but holds a dominant, differentiated position in the human challenge trial market with few direct peers of comparable scale and model validation.